Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor-Reference-Cited by-同舟云学术

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor

Published:2018-03-08 Issue:3 Volume:11 Page:330-338
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Ericsson Hans¹,Nelander Karin¹,Lagerstrom-Fermer Maria¹,Balendran Clare²,Bhat Maria²,Chialda Ligia³,Gan Li-Ming¹,Heijer Maria¹,Kjaer Magnus¹,Lambert John³,Lindstedt Eva-Lotte⁴,Forsberg Gun-Britt⁴,Whatling Carl⁴,Skrtic Stanko¹

Affiliation:

1. Early Clinical Development; AstraZeneca, Gothenburg Sweden

2. Precision Medicine and Genomics; IMED Biotech Unit; AstraZeneca Gothenburg Sweden

3. PAREXEL International; Northwick Park Hospital; Harrow UK

4. Cardiovascular and Metabolic Diseases; AstraZeneca, Gothenburg Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12546/fullpdf

Reference19 articles.

1. Traditional risk factors versus biomarkers for prediction of secondary events in patients with stable coronary heart disease: from the Heart and Soul study;Beatty,;J. Am. Heart Assoc.,2015

2. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine,;N. Engl. J. Med.,2017

3. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker,;N. Engl. J. Med.,2017

4. Anti-inflammatory therapies for cardiovascular disease

5. Leukotrienes;Peters-Golden;N. Engl. J. Med.,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions;Biomedicines;2024-07-26

2. A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam;British Journal of Clinical Pharmacology;2024-06-03

3. Novel thiazolopyridine derivatives of diflapolin as dual sEH/FLAP inhibitors with improved solubility;Bioorganic Chemistry;2023-10

4. Evolving Diagnostic and Management Advances in Coronary Heart Disease;Life;2023-04-05

5. Exploiting the Physical Properties of Diethanolamine Boronic Esters for Process Improvements in AZD5718;Organic Process Research & Development;2023-03-09